Komala Pillay

Komala Pillay

Auto-generated profile, based on publicly available information

Komala Pillay

University of Cape Town

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2010 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
JWJo Wilmshurst
Jo Wilmshurst
SLS. Lillis
S. Lillis
HZH. Zhou
H. Zhou
KPK. Pillay
K. Pillay
HHH. Henderson
H. Henderson
HJHeinz Jungbluth
Heinz Jungbluth

6 February 2008 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
GVGiuseppe Viale
Giuseppe Viale
OGOn the behalf of the International Breast Cancer Study Group
On the behalf of the International Breast Cancer Study Group
MRMeredith M. Regan
Meredith M. Regan
Mauro MastropasquaMauro Mastropasqua
Mauro Mastropasqua
FMFausto Maffini
Fausto Maffini
ACAlan S. Coates
Alan S. Coates
Several small studies have reported that having a high percentage of breast tumor cells that express the proliferation antigen Ki-67 (ie, a high Ki-67 labeling index) predicts better response to neoadjuvant chemotherapy. However, the predictive value of a high Ki-67 labeling index for response to adjuvant chemotherapy is unclear. To investigate whether Ki-67 labeling index predicts response to adjuvant chemoendocrine therapy, we assessed Ki-67 expression in tumor tissue from 1924 (70%) of 2732 patients who were enrolled in two randomized International Breast Cancer Study Group trials of adjuvant chemoendocrine therapy vs endocrine therapy alone for node-negative breast cancer. A high Ki-67 labeling index was associated with other factors that predict poor prognosis. Among the 1521 patients with endocrine-responsive tumors, a high Ki-67 labeling index was associated with worse disease-free survival but the Ki-67 labeling index did not predict the relative efficacy of chemoendocrine therapy compared with endocrine therapy alone. Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies.

20 March 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GVGiuseppe Viale
Giuseppe Viale
MRMeredith M. Regan
Meredith M. Regan
Eugenio MaioranoEugenio Maiorano
Eugenio Maiorano
Mauro MastropasquaMauro Mastropasqua
Mauro Mastropasqua
RGRastko Golouh
Rastko Golouh
ACAlan S. Coates
Alan S. Coates
Purpose: To centrally assess estrogen receptor (ER) and progesterone receptor (PgR) levels by immunohistochemistry and investigate their predictive value for benefit of chemo-endocrine compared with endocrine adjuvant therapy alone in two randomized clinical trials for node-negative breast cancer. Patients and Methods: International Breast Cancer Study Group Trial VIII compared cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy for 6 cycles followed by endocrine therapy with goserelin with either modality alone in pre- and perimenopausal patients. Trial IX compared three cycles of CMF followed by tamoxifen for 5 years versus tamoxifen alone in postmenopausal patients. Central Pathology Office reviewed 883 (83%) of 1,063 patients on Trial VIII and 1,365 (82%) of 1,669 on Trial IX and determined ER and PgR by immunohistochemistry. Disease-free survival (DFS) was compared across the spectrum of expression of each receptor using the Subpopulation Treatment Effect Pattern Plot methodology. Results: Both receptors displayed a bimodal distribution, with substantial proportions showing no staining (receptor absent) and most of the remainder showing a high percentage of stained cells. Chemo-endocrine therapy yielded DFS superior to endocrine therapy alone for patients with receptor-absent tumors, and in some cases also for those with low levels of receptor expression. Among patients with ER-expressing tumors, additional prediction of benefit was suggested in absent or low PgR in Trial VIII but not in Trial IX. Conclusion: Low levels of ER and PgR are predictive of the benefit of adding chemotherapy to endocrine therapy. Low PgR may add further prediction among pre- and perimenopausal but not postmenopausal patients whose tumors express ER.

1 December 2013 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SMSandra Mercier
Sandra Mercier
SKSébastien Küry
Sébastien Küry
GSGasnat Shaboodien
Gasnat Shaboodien
DHDarren T. Houniet
Darren T. Houniet
NKNonhlanhla P Khumalo
Nonhlanhla P Khumalo
BMBongani M. Mayosi
Bongani M. Mayosi

28 October 2002 in Histopathology
Verified
Journal Article
Closed access
PDF file
KPK Pillay
K Pillay
DGD Govender
D Govender
RCR Chetty
R Chetty

27 February 2004 in Histopathology
Verified
Journal Article
Closed access
PDF file
KPK Pillay
K Pillay
RSR Solomon
R Solomon
JDJ D Daubenton
J D Daubenton
CSC C Sinclair‐Smith
C C Sinclair‐Smith